Ongoing Clinical Trials for Piriformis Syndrome
Currently, there are 3 clinical trials investigating treatments for piriformis syndrome. These studies are being conducted in France, the Netherlands, and Italy, testing various approaches including botulinum toxin injections to help relieve pain and improve quality of life for patients with this condition.
Clinical trial locations
- France
- Italy
- Netherlands
Study of botulinum toxin injections to treat pain in patients with piriformis muscle syndrome
This French study is investigating whether injections of botulinum toxin (XEOMIN) can help reduce pain in people with piriformis muscle syndrome. The condition occurs when the piriformis muscle in the buttock region compresses the sciatic nerve, causing pain and discomfort that can extend down the leg.
Who can participate: You may be eligible if you are between 18 and 80 years old and have been diagnosed with the condition for at least 3 months on one side of your body. Your diagnosis must be confirmed with a score of 8 or higher on a specialized scoring system, and your pain level must be at least 4 points on a pain scale. Importantly, previous treatments such as physiotherapy, muscle relaxants, and pain medications must not have worked for you. You must not have a herniated disc in your lower back that could explain your pain, as confirmed by MRI or CT scan.
Who cannot participate: You cannot join this study if you are younger than 18 or older than 65, have a known allergy to botulinum toxin, or have received botulinum toxin treatment in the past 6 months. Pregnant or breastfeeding women are excluded, as are people with neuromuscular disorders, active infections at the injection site, bleeding disorders, or those taking blood thinners. If you have had back surgery in the past year, have nerve root compression confirmed by imaging, or are participating in another clinical trial, you will not be eligible.
What the study involves: Participants will receive a single injection of either XEOMIN (containing up to 200 units of botulinum toxin) or a placebo directly into the affected muscle. The injection is guided by ultrasound or CT scan to ensure accurate placement. Neither you nor your doctor will know which treatment you receive. The study will monitor your progress over 6 months, with follow-up visits at 6, 12, 18, and 24 weeks. At each visit, your pain levels will be assessed, and you will complete questionnaires about your quality of life, physical functioning, and any side effects. Some patients may receive a second injection at 12 weeks if needed.
Investigational drug: The medication being tested is botulinum toxin, which works by blocking nerve signals to muscles, causing them to relax. This relaxation reduces pressure on the sciatic nerve and may help relieve pain in patients who have not responded to other treatments.
Study on the Effect of Botulinum Toxin Type A and Physiological NaCl 0.9% in Patients with Piriformis Syndrome
This Dutch trial is examining whether Botox (botulinum toxin type A) injections can help people with piriformis syndrome return to sports activities. The study focuses on patients whose piriformis muscle has become tight and is causing pain that interferes with their ability to participate in sports.
Who can participate: You may be eligible if you are between 18 and 60 years old and actively participate in a sport where walking is involved. You must have experienced a positive effect from a test block using lidocaine and methylprednisolone, meaning that when these medicines were used, you felt an improvement in your condition.
Who cannot participate: You cannot participate if you are not between 18 and 65 years old, are not experiencing piriformis hypertonia (muscle tightness in the buttock area), or are not able to resume sports activities after receiving a botulinum toxin injection. Individuals who are considered part of a vulnerable population requiring special protection or care are also excluded.
What the study involves: After confirming your eligibility, you will undergo an initial assessment to evaluate your condition before treatment begins. You will then receive an injection of botulinum toxin type A into the affected muscle. The study will monitor your progress regularly, with the primary focus on assessing whether you can resume sports activities after the injection. If treatment is discontinued, a follow-up visit is scheduled at the outpatient clinic 12 weeks after the initial test block. The trial is estimated to conclude by December 2024.
Investigational drug: The medication being tested is Botox, which is injected into the affected muscle to help relieve pain and improve muscle function. It works by blocking the release of acetylcholine, a chemical responsible for muscle contraction, allowing the muscle to relax and potentially enabling patients to return to their sports activities.
Study Comparing the Speed of Action of Ibuprofen Lysine and Ibuprofen in Treating Acute Pain in Children
This Italian study is comparing two pain relief medications in children: ibuprofen lysine suspension and regular ibuprofen suspension. The goal is to determine which medication works faster to relieve acute pain in children aged 4 to 12 years.
Who can participate: Children between 4 and 12 years old may be eligible if they have been admitted to the emergency room with acute pain as their main or additional symptom. This can include pain from sore throat, headache, ear pain, toothache, or injuries. The child’s pain level must be 4 or higher on a scale of 1 to 10. Both parents or guardians and the children themselves must provide written informed consent and be willing to follow the study’s requirements.
Who cannot participate: Children outside the 2 to 12 years age range cannot participate. Other exclusions include children with serious health conditions that might interfere with the study, those currently taking other medications that might affect results, those with allergies to ibuprofen or similar medications, children with a history of stomach problems such as ulcers or bleeding, those with kidney or liver problems, children with asthma worsened by aspirin or NSAIDs, and those participating in another clinical trial.
What the study involves: After the initial assessment confirming eligibility, children will receive either lysin ibuprofen suspension or regular ibuprofen suspension orally. The child’s pain levels will be assessed using age-appropriate scales at 5 minutes after medication administration (the primary assessment), with additional assessments at 10, 20, and 30 minutes. Throughout the study, participants will be monitored for any side effects to ensure their safety and well-being.
Investigational drugs: The study is testing two medications. Lysin ibuprofen suspension is designed to work quickly to relieve pain, with the addition of lysin intended to help the body absorb ibuprofen faster. Regular ibuprofen suspension is a common pain reliever and anti-inflammatory medication used to reduce fever and relieve pain. Both are administered as liquid suspensions suitable for children.
Summary
The three clinical trials for piriformis syndrome represent different approaches to managing this painful condition. Two of the studies, conducted in France and the Netherlands, focus specifically on using botulinum toxin injections to treat the muscle tightness and pain associated with piriformis syndrome. Both trials aim to help patients who have not found relief through conventional treatments like physiotherapy and pain medications. The French study takes a comprehensive approach by monitoring patients over 6 months and evaluating multiple aspects of quality of life, while the Dutch study focuses particularly on helping active individuals return to sports activities.
The third trial, taking place in Italy, examines pain management in a pediatric population, comparing two forms of ibuprofen for treating acute pain in children. While this study is not exclusively focused on piriformis syndrome, it addresses acute pain conditions that may include musculoskeletal pain similar to what might be experienced with this condition.
Geographically, these trials span three European countries, with each study bringing a unique perspective to pain management. The emphasis on botulinum toxin in two of the three trials highlights growing interest in this treatment approach for muscle-related pain conditions. All three studies are designed with careful safety monitoring and use validated assessment tools to measure treatment effectiveness.
